Arcutis Biotherapeutics Inc (ARQT)
9.43
+0.17
(+1.84%)
USD |
NASDAQ |
Nov 18, 16:00
9.53
+0.10
(+1.06%)
Pre-Market: 08:38
Arcutis Biotherapeutics Enterprise Value: 977.78M for Nov. 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 18, 2024 | 977.78M |
| November 15, 2024 | 957.88M |
| November 14, 2024 | 1.036B |
| November 13, 2024 | 1.100B |
| November 12, 2024 | 1.074B |
| November 11, 2024 | 1.143B |
| November 08, 2024 | 1.140B |
| November 07, 2024 | 1.091B |
| November 06, 2024 | 1.005B |
| November 05, 2024 | 962.56M |
| November 04, 2024 | 894.68M |
| November 01, 2024 | 888.82M |
| October 31, 2024 | 846.31M |
| October 30, 2024 | 870.88M |
| October 29, 2024 | 875.56M |
| October 28, 2024 | 893.11M |
| October 25, 2024 | 897.79M |
| October 24, 2024 | 858.01M |
| October 23, 2024 | 850.99M |
| October 22, 2024 | 849.82M |
| October 21, 2024 | 846.31M |
| October 18, 2024 | 894.28M |
| October 17, 2024 | 984.37M |
| October 16, 2024 | 1.011B |
| October 15, 2024 | 967.99M |
| Date | Value |
|---|---|
| October 14, 2024 | 1.014B |
| October 11, 2024 | 1.019B |
| October 10, 2024 | 1.018B |
| October 09, 2024 | 1.021B |
| October 08, 2024 | 1.007B |
| October 07, 2024 | 1.019B |
| October 04, 2024 | 1.046B |
| October 03, 2024 | 1.065B |
| October 02, 2024 | 1.071B |
| October 01, 2024 | 991.39M |
| September 30, 2024 | 962.14M |
| September 27, 2024 | 935.47M |
| September 26, 2024 | 912.09M |
| September 25, 2024 | 905.08M |
| September 24, 2024 | 972.88M |
| September 23, 2024 | 967.03M |
| September 20, 2024 | 1.028B |
| September 19, 2024 | 1.027B |
| September 18, 2024 | 1.057B |
| September 17, 2024 | 1.054B |
| September 16, 2024 | 1.029B |
| September 13, 2024 | 1.087B |
| September 12, 2024 | 1.071B |
| September 11, 2024 | 1.071B |
| September 10, 2024 | 1.112B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
123.06M
Minimum
Oct 23 2023
1.552B
Maximum
Feb 08 2021
769.99M
Average
788.85M
Median
Enterprise Value Benchmarks
| Mirum Pharmaceuticals Inc | 2.012B |
| Biogen Inc | 27.61B |
| Vertex Pharmaceuticals Inc | 113.74B |
| NovaBay Pharmaceuticals Inc | 2.70M |
| Palatin Technologies Inc | 16.19M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -41.54M |
| Revenue (Quarterly) | 44.76M |
| Total Expenses (Quarterly) | 83.82M |
| EPS Diluted (Quarterly) | -0.33 |
| Gross Profit Margin (Quarterly) | 87.70% |
| Profit Margin (Quarterly) | -92.81% |
| Earnings Yield | -18.98% |
| Normalized Earnings Yield | -18.98 |